深耕精准医疗赛道，吉因加完成3亿元D轮融资

Group 1 - Geneplus has completed a 300 million yuan Series D financing round, with investments from Shaoxing City Yuecheng District Science and Technology Innovation Fund and Beijing Changping Industrial Development Investment Fund among others [2][3] - The financing will primarily be used for the research and development of AI multi-omics technology, expansion of biomarker innovation pipelines, and deepening of global service networks, enhancing the company's capabilities in precision diagnostics and new drug development [3] - Geneplus, established in April 2015, focuses on precision medicine and has created an AI-driven multi-omics platform, achieving significant breakthroughs in tumor MRD monitoring and integrated NGS precision diagnostic platforms [3] Group 2 - The company aims to convert AI multi-omics innovative technologies into accessible and reliable clinical solutions, with plans to increase investment in AI multi-omics R&D and accelerate the commercialization of core products like MRD monitoring and early tumor screening [3] - Following the Series D financing, Geneplus will continue to deepen its "AI + multi-omics + full-chain" development strategy, solidifying its leading position in precision diagnostics while enhancing its full-process service capabilities for new drug development [3] - The company is committed to exploring innovative applications of AI in precision medicine to improve domestic diagnostic levels and contribute to public health [3]